Chen, X. et al. (2023) 'Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.,' Journal of Clinical Oncology, 41(16_su...
新闻来源:UCLA opens CAR T clinical trial targeting most common types of lymphoma and leukemia 2019年10月,加州大学洛杉矶分校琼森综合癌症中心启动了一项开创性的嵌合抗原受体(CAR)T细胞(CAR-T)免疫疗法临床试验。在这项临床试验中,CAR-T细胞将通过同时识别在B细胞淋巴瘤和白血病细胞表面上表达的两个靶标--- C...
Adoptive cell therapies (ACTs) have been used to treat cancer for over 30 years. The rationale that led to the chimeric antigen receptor-modified T (CAR T)-cells was to overcome the HLA restriction, the effective presentation of target epitopes, and the lack of a broad TCR gene repertoire ...
[1]Cwynarski K,et al.TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial[J]. Nature Medicine, 2024: 1-7.https://www.nature.com/articles/s41591-024-03326-7 [2]Derigs P,et al.Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic ...
T-cell lymphomaDeveloping CAR T-cells for T-lineage malignancies requires minimizing fratricide of engineered T-cells and mitigating the risk of T-cell aplasia, which may be caused by the off-tumor activity of CAR T-cells. We have developed and optimized for clinical evaluation a CAR targeting...
Cellular therapy increases survival in recurring B-cell lymphoma: Clinical trialhttps://medicalxpress.com/news/2024-02-cellular-therapy-survival-recurring-cell.html版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不...
N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 15, 31–46 (2018). CAS PubMed Google Scholar Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)....
高博医学（血液病）北京研究中心北京高博博仁医院潘静主任聚焦自体 CD7 CAR-T 治疗难治/复发急性T淋巴细胞白血病/淋巴瘤（r/r T-ALL/LBL），在大会发言中分享了题为“Autologous CD7 CAR T-Cell Therapy for Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma”的最新研究成果。此前，潘静主任...
16. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells [J]. Blood, 2012, 119(12): p. 2709-20. doi: 10.1182/blood-2011-10-...
The first such product, tisagenlecleucel, has recently been approved for clinical therapy of refractory B cell acute lymphoblastic lymphoma (ALL). More and more clinical trials of CAR-T cells are being done throughout the world [26,27,28,29,30,31,32,33,34,35,36,37,38]. In recent ...